greeksoup/ stock research

SBC Medical Group Holdings Inc.: Q1 FY2026 earnings call

What management said about Q1 FY2026, from the documents filed with the SEC on 14 May 2026: press release. The quarter’s numbers.

Key takeaways

  • Revenue fell 9% on fee change: Total revenues were $43.1 million, down 9% from $47.3 million a year earlier. Management attributed the decline mainly to the franchise fee structure revision made in April 2025. Source
  • Net income fell 47%: Net income attributable to the company was $11.3 million, down 47%. Net income margin was 26%, down 19 percentage points. Basic and diluted EPS was $0.11, against $0.21, down 48%. Source
  • EBITDA fell 26%, margin 43%: EBITDA was $18.4 million, down 26%. EBITDA margin was 43%, down 10 percentage points year over year. Source
  • Customer count up 10%: Customers in the last twelve months numbered 6.76 million, up 10% year over year. The count covers SBC brand, Rize, Gorilla, AHH and JUN clinics, per the release footnote. Source
  • Cost of revenues rose to $12.7M: Cost of revenues was $12.7 million, up from $9.6 million. Gross profit fell to $30.3 million from $37.7 million while revenue declined. Source
  • Operating income fell to $17.7M: Income from operations was $17.7 million, down from $24.2 million. Income before income taxes was $18.9 million, and income tax expense was $7.5 million, down from $10.0 million. Source
  • Operating cash flow reached $9.2M: Net cash provided by operating activities was $9.2 million, against $1.9 million a year earlier. Cash paid for income taxes was $8.8 million, against $20.6 million. Source

“Excluding this structural change, the performance of our core business remained solid.”

Yoshiyuki Aikawa, Chairman and Chief Executive Officer

What changed from last quarter

  • New: Longevity and AI were added to the stated priorities. The prior release listed three priorities, without these two. Source
  • New: EBITDA is now calculated by adding only depreciation and amortization to income from operations. The prior release also added impairment loss on intangible assets. Source

Results and growth drivers

  • Revenue fell 9% on fee change: Total revenues were $43.1 million, down 9% from $47.3 million a year earlier. Management attributed the decline mainly to the franchise fee structure revision made in April 2025. Source
  • Net income fell 47%: Net income attributable to the company was $11.3 million, down 47%. Net income margin was 26%, down 19 percentage points. Basic and diluted EPS was $0.11, against $0.21, down 48%. Source
  • EBITDA fell 26%, margin 43%: EBITDA was $18.4 million, down 26%. EBITDA margin was 43%, down 10 percentage points year over year. Source
  • Prior-year life insurance gain absent: Total other income was $1.1 million, against $7.2 million a year earlier. The prior-year quarter included an $8.7 million gain on redemption of life insurance policies, with none in the current quarter. Source
  • Revenue up from fourth quarter: Revenue of $43.1 million compares with $39.6 million for the fourth quarter of 2025, as shown in the prior release.

Revenue mix and customers

  • Related-party revenue fell, other rose: Revenue from related parties was $38.0 million, against $45.3 million. Revenue from other customers was $5.1 million, against $2.1 million. The release does not explain the shift. Source
  • Customer count up 10%: Customers in the last twelve months numbered 6.76 million, up 10% year over year. The count covers SBC brand, Rize, Gorilla, AHH and JUN clinics, per the release footnote. Source
  • Franchise locations up by 33: Franchise locations numbered 284 at March 31, 2026, up 33 from a year earlier. The count includes OrangeTwist alongside the SBC brand, Rize, Gorilla, AHH and JUN clinics. Source
  • Repeat visits at 72%: Customers who visited franchisee clinics twice or more made up 72% of the customer count, excluding free counseling, as the release defines it. Source

“In terms of profitability, our net income margin was 26%, and our EBITDA margin remained at a high level of 43%.”

Yoshiyuki Aikawa, Chairman and Chief Executive Officer

Costs and profitability

  • Cost of revenues rose to $12.7M: Cost of revenues was $12.7 million, up from $9.6 million. Gross profit fell to $30.3 million from $37.7 million while revenue declined. Source
  • SG&A expense eased: Selling, general and administrative expenses were $12.6 million, down from $13.5 million. Related-party SG&A was $343,393 in the quarter, against nil a year earlier. Source
  • Operating income fell to $17.7M: Income from operations was $17.7 million, down from $24.2 million. Income before income taxes was $18.9 million, and income tax expense was $7.5 million, down from $10.0 million. Source

Cash flow and balance sheet

  • Operating cash flow reached $9.2M: Net cash provided by operating activities was $9.2 million, against $1.9 million a year earlier. Cash paid for income taxes was $8.8 million, against $20.6 million. Source
  • Cash balance rose to $167.3M: Cash and cash equivalents were $167.3 million at March 31, 2026, up from $163.8 million at December 31, 2025. Exchange rate effects on cash were a $3.3 million decrease. Source
  • Bank debt repaid by $1.8M: Repayments of bank and other borrowings were $1.8 million, and finance lease repayments were $37,278. Total bank and other borrowings were $40.4 million at quarter end. Source
  • Translation turned to loss: Foreign currency translation was a $4.2 million loss, against a $9.8 million gain a year earlier. Accumulated other comprehensive loss rose to $61.5 million from $57.3 million. Source

“With the goal of building a sustainable and continuously growing healthcare platform.”

Yoshiyuki Aikawa, Chairman and Chief Executive Officer

Capital and shareholder returns

  • Return on equity at 18%: Return on equity was 18% on an annualized basis, down 23 percentage points. The release defines it as net income attributable to the company over average shareholders' equity. Source
  • Equity rose to $270.4M: Total stockholders’ equity was $270.4 million at March 31, 2026, up from $263.3 million. Retained earnings rose by the net income attributable to the company. Source
  • No share repurchase in quarter: The cash flow statement shows no repurchase of common stock in the quarter. Treasury shares stayed at 1,304,308, and shares outstanding stayed at 102,576,943. Source
  • Weighted share count edged down: Weighted average shares for basic and diluted EPS were 102,576,943, against 103,276,637 a year earlier. Source

Strategy, investment and reporting

  • Three priorities continue: Management said it will keep promoting its multi-brand aesthetic dermatology strategy, expanding non-aesthetic medical business and strengthening its overseas operational foundation. Source
  • Equity and goodwill balances steady: Equity method investments stayed at $20.3 million and goodwill was $15.4 million at March 31, 2026. Intangible assets, net, were $47.2 million. Source
  • Capital spending stayed small: Purchases of property and equipment were $0.1 million and prepayments for property and equipment were $0.4 million, against $0.3 million and $0.5 million a year earlier. Source
  • Non-GAAP measures reconciled to GAAP: The release reconciles EBITDA and EBITDA margin to income from operations, and net income margin to net income attributable to the company. Management says these help identify underlying trends. Source

Figures management reported

FigureReported
Number of customers, last twelve months (patient volumes) Source6.76 million, up 10% year over year

Earlier plans management reported on

  • Not stated: The prior release said the 2024 restructuring and the April 2025 fee revision had financial impact now largely behind the company. This release does not restate that view.
  • Not stated: The prior release said the company was well-positioned to return to sustainable top-line growth. This release does not repeat that statement.
  • Not stated: The prior release set out three priorities for 2026. This release continues the same three areas.

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.